CNC — Centene Corp.

The market mood around CNC is positive after Q2 2026 earnings beat estimates, management raised FY2026 adjusted EPS guidance to greater than $4.80, and the health benefits ratio trend was stronger than feared in Commercial and Medicare. Analyst positioning reflects 27 buy ratings, 16 holds, and only 1 sell, with a consensus target of $68.29. The stock is up roughly 60% YTD and near its 52-week high, though the August 26 insider sale by the General Counsel and the CFO transition are minor caution flags.

The 12-quarter FMP income statement is dominated by a massive, non-cash 2025 impairment: Q3 2025 booked a -$13.50 EPS / -$6.6B net loss and Q4 2025 another -$2.24 EPS, which is why trailing GAAP EPS is -$10.33. Ignore that for run-rate purposes. H1 2026 is the real story: GAAP EPS was $3.11 in Q1 and $2.19 in Q2, for a $5.30 six-month total versus $2.12 in H1 2025. H1 2026 free cash flow was $7.6B versus $2.95B in H1 2025, a clear operating inflection. Revenue is harder to read: FMP shows Q2 2026 revenue of $44.4B, down 8.9% YoY, while the company's Q2 release cited $53.6B total revenue; the FMP line is likely on a different basis (possibly net of premium taxes), so I put more weight on margins and cash flow than on the single-quarter revenue print. Underlying operating margins in 2026 are about 3-4% of revenue, consistent with managed care economics. This is a cyclical/turnaround inflection, not a smooth growth story.

On trapped GAAP numbers, CNC looks cheap-and-broken: TTM P/E is -6.3x and P/S is 0.167x versus a 5-year average of 0.25x. The more decision-useful metric is forward valuation: $65.34 divided by $4.80 FY26 consensus EPS is about 13.6x, which is reasonable for managed care and well below the distorted 5-year average P/E of 24.85x. P/B of 1.43x also does not scream expensive. The balance sheet is okay: cash of $24.2B exceeds long-term debt of $16.0B, though much of that cash is likely regulatory capital. Overall, CNC is fairly priced to modestly cheap on forward earnings, with the discount versus its own history partly deserved because of thin, government-dependent margins.

The stock has already made the recovery move: from a 52-week low of $28.24 to $65.34 is roughly +130%, and it sits within ~6% of the high. At 13.6x forward EPS, the market is underwriting a successful turnaround, not offering a free option on one. If Centene delivers $4.80+ this year and can grow 2027 EPS to ~$5.30-5.50, the stock is reasonably valued with upside toward analyst targets. If H2 medical costs re-accelerate and EPS lands closer to $4.30, the multiple would look less comfortable and the stock could give back some of the 2026 gains. In short: the easy mispricing is gone; the remaining edge depends on execution versus elevated expectations.

As of 2026-08-27, RSI(14) was 51.01, right in the neutral zone, and the price was essentially flat to its 20-day and 50-day moving averages (+0.2% and +0.3% respectively). The bigger signal is the 200-day line: price is +32.2% above it, so the long-term trend is strongly up while short-term momentum has been consolidating just under the 52-week high of $69.36. This is not an overbought setup, but it is also not a low-risk entry. A breakout above $69.36 or a pullback to the 20/50-day zone would give a more obvious entry than the current in-between technical position.

• Medicaid redeterminations and membership attrition: enrollment losses can pressure revenue even when the remaining risk mix improves.
• Medicare Advantage rate setting and Star ratings: reimbursement and quality bonus changes directly hit HBR and margins.
• ACA exchange subsidy and federal policy risk: Centene's Marketplace book depends on continued government support.
• Health-care cost/utilization trends: H2 2026 re-acceleration would squeeze the 89.6% total HBR, especially the 93.9% Medicaid ratio.
• Interest rates and debt refinancing: $16.0B of long-term debt and prior note redemptions make capital allocation and rates relevant to FCF.

• Q3 2026 earnings (late Oct/early Nov 2026) - the first clean read on whether HBR improvement persists without the ~$0.50 of non-recurring FY26 benefits.
• CFO transition comments from incoming CFO Chris Neczypor (Sep 2026-Jan 2027) on capital allocation, buybacks, and M&A appetite.
• Potential FY26 guidance raise or early 2027 Medicare/Medicaid rate commentary.
• Analyst re-ratings: Argus's new $80 Buy target shows upside if sentiment continues to build.

• Medical cost trend re-acceleration: with total HBR at 89.6% and Medicaid at 93.9%, there is very little room for utilization or acuity surprises.
• Government payer risk: Medicaid, Medicare Advantage, and ACA exchange economics are exposed to reimbursement cuts, rate-setting changes, and redetermination swings.
• Earnings quality/comparability: ~$0.50 of the FY26 guidance bump comes from non-recurring items, so FY27 faces a tougher comparable.
• CFO transition and key-person/execution risk during a critical recovery period.
• Impairment/balance-sheet history: multi-billion-dollar write-downs in 2025 and a re-levered-ish balance sheet make further goodwill/intangibles scrutiny important.

This is a genuine operating turnaround with strong cash-flow confirmation: H1 2026 FCF was $7.6B, Q1/Q2 GAAP EPS totaled $5.30, and the accruals ratio is negative, meaning cash earnings are backing reported earnings. But at ~$65 and 13.6x forward EPS, the recovery is largely priced in, and the structural exposure to thin government margins limits how much I would pay. I would not chase at this level; it looks like a balanced, hold/watch candidate until Q3 confirms the HBR story or price gives a better entry.

Calculated by applying a 14.0x P/E multiple to FY2026 consensus adjusted EPS of $4.80. The 14.0x multiple is a reasonable managed-care multiple slightly below CNC's own 5-year average P/E, reflecting solid but policy-sensitive, thin-margin economics; 14.0 x $4.80 = $67.20.